A PHP Error was encountered
Severity: Warning
Message: Trying to access array offset on value of type null
Filename: views/press_details.php
Line Number: 14
Backtrace:
File: /home/reportsweb/public_html/application/views/press_details.php
Line: 14
Function: _error_handler
File: /home/reportsweb/public_html/application/controllers/Press_controller.php
Line: 112
Function: view
File: /home/reportsweb/public_html/index.php
Line: 316
Function: require_once
Research Applications Segment to Grow Significantly During 2021–2028
According to our latest research study on “Leukapheresis Market Forecast to 2028 – COVID-19 Impact and Global Analysis – Product Type, Application, and End User,” the market is projected to reach US$ 133.90 million by 2028 from US$ 74.48 million in 2021; it is estimated to grow at a CAGR of 8.7% from 2021 to 2028. The report highlights trends prevailing in the market and the factors driving and restraining the market growth.
Leukapheresis is a procedure that has white blood cells (leukocytes) involved in the body's immune response are segregated from a blood sample. It is a particular form of apheresis in which an element of blood, such as red blood cells or platelets, is obtained while the remaining blood is restored to circulation. Leukapheresis is often used to reduce very high white blood cell (WBC) counts, such as chronic blood cancers like chronic lymphocytic leukemia (CLL). It can also be completed to obtain white blood cells for later transplant, such as to manage abrupt declines in WBC counts throughout cancer chemotherapy. Another use is as a section of a novel form of immunotherapy, termed chimeric antigen receptor (CAR) T-cell therapy, to help fight leukemia, prostate cancer, and other forms of cancers. Leukapheresis can be completed on the person claiming treatment (autologous apheresis) or on a donor for a later transplant (allogeneic apheresis). Currently, leukapheresis is commonly used to treat various diseases, and it is also used for diagnostic purposes as it can increase circulating tumor cells yields.
Based on application, the leukapheresis market is bifurcated into research applications and therapeutic applications. In 2021, the research applications segment held a larger share of the market and the same segment is expected to register a higher CAGR during the coming years.
Asahi Kasei Corporation, Fresenius SE & Co. KGaA, Haemonetics Corporation Terumo Corporation, STEMCELL Technologies Inc., HemaCare, Macopharma, AllCells, STEMEXPRESS, and BioIVT are a few leading companies operating in the leukapheresis market..
Report segments leukapheresis market as follows:
The leukapheresis market is segmented on the basis of product type, application, and end user. Based on product type, the market is bifurcated into leukapheresis devices and leukapheresis disposables. By application, the market is bifurcated into research applications and therapeutic applications. Based on end user, the market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, blood component providers and blood centers, and hospitals and transfusion centers.
By Geography
- North America
- Europe
- France
- Germany
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific (APAC)
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East & Africa (MEA)
- Saudi Arabia
- UAE
- South Africa
- Rest of Middle East & Africa
- South and Central America (SCAM)
- Brazil
- Argentina
- Rest of South and Central America
Contact UsContact Person: Sameer JoshiPhone: +1-646-491-9876Email Id: sales@reportsweb.com
